Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5
Robert A. Ogert(Merck & Co., Inc., Rahway, NJ, USA (United States)), John A. Howe(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lisa Wojcik(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nicholas Murgolo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert Ralston(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lisa M. Dunkle(Merck & Co., Inc., Rahway, NJ, USA (United States)), José S. Duca(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yan Hou(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lei Ba(Aaron Diamond AIDS Research Center)
Cited by 40
Related Papers
Antibiotic Susceptibility Profiles of <i>Escherichia coli</i> Strains Lacking Multidrug Efflux Pump Genes
|Antimicrobial Agents and Chemotherapy|2001|502
Selective small-molecule inhibition of an RNA structural element
|Nature|2015|419
Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation
|Biochemical Journal|2006|272